Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy

Abstract

Regadenoson was approved for clinical use in Europe in 2011. Since then, it has become the default form of stress at our institution. We have assessed the side-effect profile and tolerability of regadenoson in patients undergoing clinically indicated myocardial perfusion scintigraphy between July 2011 and July 2012. Clinical, stress and imaging data were… (More)
DOI: 10.1007/s00259-013-2619-0

Topics

9 Figures and Tables

Cite this paper

@inproceedings{Brinkert2013RegadenosonIE, title={Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy}, author={Miriam Brinkert and Eleida Reyes and Sandy Walker and Kate Latus and Annelies Maenhout and Ryu Mizumoto and C. Nkomo and Katherine Standbridge and Kshama Wechalekar and S. R. Underwood}, booktitle={European Journal of Nuclear Medicine and Molecular Imaging}, year={2013} }